New drugs in the treatment of bacterial infections

Abstract

Introduction. The use of antibacterials has become increasingly strained due to increased rates of resistance & with less development of new agents. As a result, multi-, extensively-, and pan-drug resistant bacterial strains are now frequently encountered. Purpose. To highlight recently developed antibacterial medicines and their role in clinical practice. results. 11 new antibiotics that have been approved since 2017, New drug Pretomanid is an antimycobacterial indicated, as part of a combination regimen(fig-1). Cefiderocol for the treatment of urinary tract infections and acute pyelonephritis. Also as first-line therapy for Infection-related Ventilator-Associated Complications, Hospital-acquired pneumonia & Ventilator-associated pneumonia (fig 2). Ceftazidime-avibactam licensed for carbapenemase producers(fig 3). In adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of C. difficile infection (fig 4). Conclusions. New antibacterial agents are mainly derivatives of existing classes. There is a significant need for novel antibacterial drugs and research.